key: cord-0989499-3xsw02d5
authors: Futagami, Hana; Sato, Hiroki; Yoshida, Ryuichi; Yasui, Kazuya; Yagi, Takahito; Fujiwara, Toshiyoshi
title: Acute acalculous cholecystitis caused by SARS-CoV-2 infection: A case report and literature review
date: 2021-12-29
journal: Int J Surg Case Rep
DOI: 10.1016/j.ijscr.2021.106731
sha: d938380d74eeffb14998b869ab003b4008ba8dbe
doc_id: 989499
cord_uid: 3xsw02d5

BACKGROUND: Emerging data indicate that gastrointestinal disorders, in addition to pulmonary dysfunction, are also hallmarks of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. CASE PRESENTATION: A 42-year-old man with maintenance hemodialysis developed high fever and dyspnea. He was positive for SARS-CoV-2 and was diagnosed with pneumonia. After treatment for SARS-CoV-2, his respiratory condition improved. However, he developed right upper quadrant pain with elevated inflammatory markers (white blood cells, 21,160/μL; c-reactive protein, 163.9 mg/L) on the 13th day. Abdominal computed tomography revealed acute acalculous cholecystitis. Percutaneous transhepatic gallbladder drainage (PTGBD) was performed together with antibiotic therapy, which resulted in improvement of symptoms. Laparoscopic cholecystectomy was performed 36 days after PTGBD. CONCLUSION: We report a rare case of acute acalculous cholecystitis (AAC) following pneumonia caused by SARS-CoV-2 infection. We also conducted a literature search to characterize SARS-CoV-2-related cholecystitis. Infection with SARS-CoV-2 is an important trigger for AAC, and appropriate therapeutic alternatives should be cautiously selected according to individual cases.

The outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was named "coronavirus disease " by the World Health Organization, and it has been a critical blow to the health care and economy worldwide.

Since the first diagnosed case of COVID-19 in December 2019, it has spread worldwide with detrimental consequences [1] . Patients infected with SARS-CoV-2 typically present with a variety of respiratory symptoms, ranging from asymptomatic disease to acute respiratory distress syndrome or respiratory failure [2] . In addition to pulmonary dysfunction, recent reports indicate that multiorgan diseases, such as gastrointestinal, cardiovascular, and renal disorders, are also a hallmark of COVID-19 [2] . Several studies have reported that some patients with SARS-CoV-2 present with gastrointestinal symptoms, such as abdominal pain, diarrhea, and vomiting [3] . Additionally, emerging data show that angiotensin-converting enzyme 2 (ACE2), which is known as the major receptor for SARS-CoV-2, is highly expressed in the gastrointestinal tract, biliary tract, pancreas, and liver cells, indicating that abdominal organs can be targeted by SARS-CoV-2 [4] . Therefore, focusing on SARS-CoV-2 as a trigger for abdominal disease will lead to the development of the management of COVID-19. Herein, we report a rare case of COVID-19 pneumonia presenting with acute acalculous cholecystitis. This case report has been written in line with the SCARE criteria [5] .

The patient was a 42-year-old man undergoing maintenance hemodialysis for renal failure. He presented to his family doctor with a chief complaint of high fever and cough and was found to be positive for SARS-CoV-2 via polymerase chain reaction (PCR) test. Five days after the onset, he was transferred to the emergency department of our hospital owing to decreased oxygen saturation. At the time of admission to our hospital, his body temperature was 38.1°C, oxygen saturation was < 90% on room air, and he complained of severe dyspnea; however, there were no abdominal symptoms. Computed progressively worsened over 3 days with increased oxygen administration (8 L/min by non-rebreather mask), and treatment with steroid pulse (methylprednisolone of 125 mg/day) was administered. Consequently, his respiratory condition gradually improved and he was weaned off oxygen on the fifth day after admission. However, he developed 

In this article, we report a rare case of cholecystitis following pneumonia J o u r n a l P r e -p r o o f caused by SARS-CoV-2 infection. Emerging evidence indicates that caution should be exercised while treating gastrointestinal symptoms in patients with SARS-CoV-2 infection [2] . Several studies have reported that ACE2 is a susceptible receptor for SARS-CoV-2, and ACE2 is highly expressed in cholangiocytes as well as type 2 alveolar cells of the lungs [4] . Additionally, ACE2 is highly expressed in the vascular endothelium, and the attachment of SARS-CoV-2 via ACE2 causes endotheliitis, leading to thromboembolism in multiple organs, including the gallbladder [7] . These findings suggest that the hepatobiliary system could be a potential target of SARS-CoV-2. Although the direct interaction between SARS-Cov-2 and AAC, such as the presence of SARS-CoV-2 in the bile, was not examined in our case, given that acalculous cholecystitis typically develops in critically ill or immunosuppressed patients and that organ hypoperfusion is one of the underlying mechanisms, we might consider SARS-CoV-2 infection as an important trigger for AAC.

To characterize SARS-CoV-2-related cholecystitis, we conducted a literature search using the PubMed database. We came across 17 cases, including our case, reporting AAC related to the infection of SARS-CoV-2 ( Table 1) following pneumonia due to SARS-CoV-2, which showed vasculitis possibly caused by SARS-CoV-2-related coagulopathy [11] . In contrast, no pathological findings consistent with vasculitis were found in our case. This suggests that when the degree of ischemia that can trigger acalculous cholecystitis is mild, pathological findings of vasculitis may improve during the waiting period before surgery.

The optimal management of AAC remains controversial, particularly when it is caused by SARS-CoV-2 infection. We classified the severity of SARS-CoV-2-related AAC cases according to the Tokyo guidelines 2018 [6] . Two of the 17 cases were classified as Grade I (mild AAC) and 14 were classified as Grade II (moderate AAC) J o u r n a l P r e -p r o o f ( Table 1) . As for the initial treatment for cases with moderate AAC, emergency cholecystectomy was performed in six patients and PTGBD in four patients. Treatment with PTGBD failed in two patients with gangrenous cholecystitis (#5 and #11), and cholecystectomy was eventually performed 3 days after PTGBD. In case #15, the patient was diagnosed with gangrenous cholecystitis. However, her general condition deteriorated rapidly, and she died of pneumonia, after failing to receive aggressive treatment for AAC. These results suggest that even with AAC caused by SARS-CoV-2, emergency cholecystectomy should be considered according to the Tokyo guidelines 2018 in cases with marked local inflammation. On the other hand, considering that there were cases in which SARS-CoV-2-related pneumonia became evident after surgery, the treatment strategy for AAC with the elevation of inflammatory markers but without marked local inflammation such as gangrenous cholecystitis should be selected cautiously. It is suggested that the infectious virus can be shed for more than 2 weeks after the onset in patients with SARS-CoV-2 who required mechanical ventilation; therefore, elective cholecystectomy followed by sufficient observation may be a safe treatment option for those cases. In such cases, PTGBD could be a useful bridging treatment option.

In conclusion, we have presented a case of AAC related to SARS-CoV-2 pneumonia and conducted a literature review to gain insight into its clinical features.

Although the pathophysiology in patients with SARS-CoV-2 has yet to be fully clarified, the SARS-CoV-2 infection might be considered as an important trigger for AAC. This report will help physicians select appropriate therapeutic options for similar situations. 

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories, then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request". 

A new coronavirus associated with human respiratory disease in China

Organ-specific manifestations of COVID-19 infection

Gastrointestinal Symptoms and Outcomes in Hospitalized Coronavirus Disease

COVID-19 and the liver

The SCARE 2020

Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines

Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos)

Acalculous Cholecystitis in Burn Patients: Is There a Role for Percutaneous Cholecystostomy?

Post COVID 19 acute acalculous cholecystitis raising the possibility of underlying dysregulated immune response, a case report

Gangrenous cholecystitis during hospitalization for SARS-CoV2 infection

COVID-19 can mimic acute cholecystitis and is associated with the presence of viral RNA in the gallbladder wall

Histopathological findings in a COVID-19 patient affected by ischemic gangrenous cholecystitis

Acalcolous Hemorrhagic Cholecystitis and SARS-CoV-2 Infection

Unusual gastrointestinal manifestations of COVID-19: two case reports

conundrum: SARS-CoV-2 is not present in bile

Acute acalculous cholecystitis on a COVID-19 patient: a case report

Coronavirus Disease 2019 in a Patient on Durable Left Ventricular Assist Device Support

COVID-19 with acute cholecystitis: a case report

Acalculous Cholecystitis Due to COVID-19, an Unusual Presentation

Gangrenous Cholecystitis as a Potential Complication of